CanSino Biologics (06185.HK) announced that its new vaccine CS-2036 under development has completed the production of the first batch of 17 million doses. CS-2036 is a vaccine based on Virus-Like Particle (VLP) technology, which is able to mimic the virus's structure, thereby triggering an immune response. CanSino Biologics' CEO Xuefeng YU stated that this is an important milestone for the company in the field of vaccines, and looks forward to CS-2036 providing more effective disease prevention solutions in the future. The completion date of CS-2036 production is October 9, 2024, marking a crucial step forward for the company in vaccine development. CanSino Biologics' research team, including CEO Xuefeng YU and Shou Bai CHAO, are satisfied with the progress of the CS-2036 vaccine development and remain optimistic about its commercial prospects.

CanSino Biologics (06185.HK) announced that its new vaccine CS-2036 under development has completed the production of the first batch of 17 million doses. CS-2036 is a vaccine based on Virus-Like Particle (VLP) technology, which is able to mimic the virus's structure, thereby triggering an immune response. CanSino Biologics' CEO Xuefeng YU stated that this is an important milestone for the company in the field of vaccines, and looks forward to CS-2036 providing more effective disease prevention solutions in the future. The completion date of CS-2036 production is October 9, 2024, marking a crucial step forward for the company in vaccine development. CanSino Biologics' research team, including CEO Xuefeng YU and Shou Bai CHAO, are satisfied with the progress of the CS-2036 vaccine development and remain optimistic about its commercial prospects.